News
Articles, industry coverage and commentary
News
Articles, industry coverage and commentary
News
-
QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)
QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity. [Frederick, MD – January 24, 2023] Precision for Medicine, the first global, precision medicine clinical research services organization, today announced […]
-
Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics
BETHESDA, Md., November 3, 2022 – Precision for Medicine, the first biomarker-driven clinical research organization (CRO) supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, announces the culmination of a groundbreaking Next Generation Sequencing (NGS) initiative which improved the accuracy and […]
-
Advaxis Presents Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA® (pembrolizumab) Updated data continue to show disease control rate of 67% in Part C, with ADXS-503 being […]
-
Precision for Medicine Receives Top Recognition in CRO Leadership Awards
BETHESDA, MD, May 3, 2022 – Precision for Medicine, the first biomarker-driven clinical research organization (CRO) supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, announces the company has received four awards from Clinical Leader and Life Science Leader’s 2022 […]
-
Deep Lens Announces Launch of Real Time Feasibility Offering to Assist in Oncology Clinical Trial Design and Site Selection
Columbus, OH – December 7, 2021 – Deep Lens, a digital healthcare company focused on revolutionizing the oncology clinical trial recruitment process through artificial intelligence solutions, today announced the launch of its Real Time Feasibility offering, a new HIPAA-compliant tool designed to identify eligible patients and select the most effective […]
-
Precision for Medicine CIR (French Research Tax Credit) Accreditation Updates
PARIS, FRANCE – 10 November 2022 — Precision for Medicine, the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, today announced that it has received updated CIR accreditation from the French Ministry of Higher Education […]
-
Precision for Medicine Announces Partnership with Trialbee to Expand and Accelerate Clinical Trial Recruitment
Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine MALMO, SWEDEN & BETHESDA, MD — August 5, 2021 – Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are […]
-
Precision Medicine Group Significantly Expands Cell and Gene Therapy Expertise with Acquisition of Project Farma
LEADING BIO-ENGINEERING AND MANUFACTURING SERVICES FIRM CATALYZES THE LAUNCH OF PRECISION’S CELL AND GENE THERAPY OFFERING—’PRECISION ADVANCE’—ADDRESSING THE UNIQUE CHALLENGES OF CELL & GENE THERAPY INNOVATORS, FROM DEVELOPMENT THROUGH COMMERCIALIZATION BETHESDA, MD—January 14, 2021—Precision Medicine Group (“PMG”) announced today it has acquired Project Farma, a patient-focused bioengineering services firm that […]
-
Precision nominated for “Best CRO” by OBN Awards
Precision for Medicine is excited to be named as one of three finalists for an OBN Award 2020 in the Best CRO category! Congratulations to our fellow finalists. The OBN Awards celebrate the UK’s most innovative life sciences companies. https://lnkd.in/dQK—x
-
Mark Clein, Co-Founder and CEO of Precision Medicine Group, delivers the keynote address for BioTrinity 2020
You can view his address at your convenience here. In the course of his presentation you will hear: The ways in which digital technology is transforming patient care and impacting clinical trials What new breakthroughs are on the horizon How precision medicine continues to advance and affect patient treatment and […]
